Introduction
11β-Hydroxylase deficiency (11OHD; OMIM _202010) is the second most common cause of congenital adrenal hyperplasia (CAH), accounting for 5-8 % of cases [1, 2] . The estimated frequency of 11OHD is 1 in 100,000-200,000 live births [3, 4] in the general population and is more common in some populations of North African origin, especially Moroccan Jews [5, 6] .
Steroid 11β-hydroxylase catalyses the conversion of 11-deoxycortisol to cortisol and also the conversion of 11-deoxycorticosterone (DOC) to corticosterone in the mitochondria of the adrenal cortex. Thus, 11OHD results in cortisol deficiency and sexual steroid excess due to the accumulation of 11-deoxycortisol and DOC precursors shunted into the androgen synthesis pathway.
Therefore, the two major consequences of this enzymatic deficit are virilisation, due to the androgen excess, and hypertension, due to the mineralcorticoid effect of DOC. The hypertension is present in two-thirds of patients with a severe deficiency [3, 4] and is usually not identified until later in childhood or in adolescence [7] . Classic 11OHD is characterized by prenatal virilisation of the female external genitalia (46,XX disorders of sex development) and precocious pseudopuberty in both sexes with
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Purpose 11β-Hydroxylase deficiency (11OHD) represents the second most common cause of congenital adrenal hyperplasia. It is caused by mutations in the CYP11B1 gene localized about 40 kb from the CYP11B2 gene with which it shares a homology of 95 %. The asymmetric recombination of these two genes is involved both in 11OHD and in glucocorticoid-remediable aldosteronism (GRA). Our objective was to set up an easy and rapid method to detect these hybrid genes and other kinds of deletions, to improve the molecular diagnosis of 11OHD. Methods A set of 8 specific probes for both the CYP11B1 and the CYP11B2 genes to be used for multiplex ligationdependent probe amplification (MLPA) analysis was designed to detect rearrangements of these genes.
Results The method developed was tested on 15 healthy controls and was proved to be specific and reliable; it led us to identify a novel chimeric CYP11B2/CYP11B1 gene in one patient that carried the known A306V mutation on the other allele. Specific amplification and sequencing of the hybrid gene confirmed the breakpoint localization in the second intron. Conclusions The MLPA kit developed enables the detection of deletions, duplications or chimeric genes and 1 3 rapid somatic growth and acceleration of bone maturation; the less severe non-classic form is characterized by mild virilisation or polycystic ovary syndrome (PCOS)-like phenotype in females and precocious pseudopuberty in both sexes, resembling non-classic 21-hydroxylase deficiency [8, 9] .
The CYP11B1 gene, responsible for 11OHD, shares a 95 % of sequence homology with the aldosterone synthase gene (CYP11B2): they are both located on chromosome 8q21, approximately 40 kb apart [10] . To date more than 90 alterations of the CYP11B1 gene associated with 11OHD have been reported in the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk).
Special cases could complicate the molecular diagnosis of 11OHD such as an unequal crossing-over between the CYP11B2 and CYP11B1 genes. Pathological alleles derived from the asymmetric recombination of these two highly homologous genes have been described. Two types of chimeric gene originate from the same recombination event: in the deleted allele, the CYP11B1 gene is under the control of the CYP11B2 promoter and thus not responding to the adrenocorticotropic hormone (ACTH) but to angiotensin II and K + , thus resulting in a reduction of cortisol production in 11OHD; in the opposite duplicated allele, the chimeric gene contains the regulatory sequence of the CYP11B1 and the structural sequence of the CYP11B2 gene causing dominantly inherited glucocorticoid-remediable aldosteronism (GRA) [11] .
The two types of CYP11B hybrids, being the result of the same recombination event, should occur with the same frequency in the population; only a few cases of CYP11B2/ CYP11B1 chimeric genes, however, have been described resulting in 11OHD to date [12] [13] [14] [15] .
Therefore, the aim of this study was to set up an easy and rapid method to detect hybrid genes and other kinds of deletions, to apply routinely to the molecular diagnosis of 11OHD. This method allowed us to identify a novel chimeric gene in a patient.
Materials and methods

Molecular analysis
The patient's and control's DNA used for this study were extracted from peripheral blood leukocytes with the Wizard Genomic DNA Purification Kit-Promega recommended by MRC-Holland MLPA protocol. Informed consent was obtained according to our institutional guidelines. The entire CYP11B1 gene was amplified in three specific overlapping fragments and automated sequenced as previously described [16] .
For the subsequent breakpoint mapping of the chimeric gene, we used the following two PCR primers: AFB2-CTCCCATGACGTGATATGTTTCCAGA specific for CYP11B2 sequence and BR-AAATCCTAATGCCCATC-CAAACCCC specific for CYP11B1 sequence. The PCR reaction was performed using the Platinum Taq DNA Polymerase (Invitrogen) with the following cycles: initial denaturation at 95 °C for 5 min; 5 cycles at 95 °C for 60 s, 60 °C for 30 s and 72 °C for 100 s; 25 cycles at 95 °C for 60 s, 57 °C for 30 s and 72 °C for 100 s + 2 s for cycle. The fragment obtained, which was about 3890 bp long, was sequenced using additional internal primers (available on request). Direct sequencing was carried out using an automated CEQ 8000 Sequencer-Beckman Coulter.
The reference sequences for the CYP11B1 and CYP11B2 genes are GenBank NG_007954.1 and GenBank NG_008374.1, respectively. The +1 numbering of the genomic DNA corresponds to the A of the ATG translation initiation codon.
Multiplex ligation-dependent probe amplification
The target sequence of each synthetic half probe was designed according to the recommendations of Stern et al [17] . All the probes were planned both to bind specifically to the non-homologous nucleotides between the CYP11B1 and CYP11B2 genes and to be used with the commercial control kit SALSA MLPA P300 Human DNA reference (MRC-Holland). A total of 8 specific probes were projected: 6 for the CYP11B1 gene and 2 for the CYP11B2 gene (Table 1; Fig. 1a ).
All the 5′ and 3′ half probes were completed with a universal primer sequence (GGTTCCCTAAGGGTTGGA and TCTAGATTGGATCTTGCTGGCAC, respectively) to be amplified by the Cy5 labelled primer pair already contained in the EK1 MLPA reagent kit (MRC-Holland, Amsterdam, the Netherlands) The 3′ half probes are phosphorylated at the 5′ end. MLPA reactions were performed starting from 100 ng of genomic DNA using the EK1 MLPA reagent kit for MLPA following the standard protocol. 1.5 μl of PCR product was separated by automated capillary electrophoresis (CEQ 8000, Beckman Coulter Inc., Brea, CA) with 0.5 μl of DNA Size Standard Kit-600 (Beckman Coulter Inc., Brea, CA). The integrated peak areas obtained from the sequencer supplemented software were exported to an Excel spreadsheet (Microsoft, Silicon Valley, CA). For each sample, the peak areas were first normalized to the average peak area of the control probes followed by normalization to the average peak area of the control samples included in the run. The sample run was considered acceptable if the ratio for the internal control probe pairs was between 0.8 and 1.2. Threshold values for deletions and duplications were set at 0.75 and 1.25, respectively.
Results
A 19-year-old male patient from Sicily was evaluated from the Endocrinological Unit of S.Orsola-Malpighi Hospital in Bologna for a suspected testicular tumour. He reported that he and his sister (not interested/available for evaluation) were probably affected by 21-hydroxylase deficiency as both of them had received that diagnosis in childhood and had been treated at that time by glucocorticoids, but only for short periods and without a continuous medical CYP11B2/CYP11B1 management/follow-up. The instrumental investigations (CT scan and MRI) confirmed that the patient had adrenal rests; he presented also short stature, acne and a mild hypertension. The analysis of the CYP21A2 gene and the hormonal assays were started simultaneously. The former did not show alterations in the CYP21A2 gene (data not shown) and the hormonal evaluation, performed by Liquid Chromatography-Tandem Mass Spectrometry, confirmed a 11OHD: decreased cortisol (1.44 ng/ml n.r. 45.7-199.4), normal 17OH-progesterone (2.06 ng/ml n.r. 0.415-2.542), increased DOC (4.05 ng/ml n.r. <0.146) and increased 11-deoxycortisol (27.05 ng/ml n.r. 0.086-1.094).
After informing the patient of the diagnosis of 11OHD, neither parents nor his sister became available for investigation, so family history is lacking.
The complete sequencing of the CYP11B1 gene showed the known A306V mutation [16, 18] in homozygosity and the absence of any heterozygous SNP thus suggesting the possibility of a deleted allele. As it was not possible to investigate the parent's samples, it was not possible to distinguish between the homozygous and hemizygous state of the A306V mutation by segregation analysis.
As a rapid and reliable method to investigate the presence of a deletion was not available on the market, a set of specific probes for MLPA was designed: it includes 8 probes, 6 specific for the CYP11B1 gene and 2 for the CYP11B2 gene (Fig. 1a) . This technique determines the copy number of the regions corresponding to the exons indicated. The method validation was performed on 15 normal controls. All probes were specific and reliable with a standard deviation <10 %.
A total of 7 patients suspected of CAH due to 11OHD were analysed by this home-made MLPA set of probes: no alterations were found, with the exception of the index case. It showed a normal value between 0.812 and 0.906 for all probes (therefore present in two copies) except two: the probe corresponding to exon 8 of the CYP11B2 gene and the probe corresponding to exon 1 of the CYP11B1 gene (mean values of 0.454 and 0.474, respectively, in three independent experiments).
As these two probes are adjacent to each other a heterozygous deletion including both of them was hypothesized (Fig. 1b) . This arrangement, considering the normal results of the other probes, is suggestive of the presence of a hybrid gene CYP11B2/CYP11B1 with a breakpoint localized between exon 2 and exon 3 of both genes (Fig. 1c) .
To confirm the formation of this chimeric gene, a specific PCR amplification was performed using a CYP11B2-specific forward primer and a CYP11B1-specific reverse primer. The result was positive and the fragment obtained (3890 bp long) was then submitted to direct sequencing with internal primers to map the breakpoint region: it lies in the second intron between the nucleotides g.2276 of the CYP11B2 gene and the nucleotide g.2400 of the CYP11B1 gene.
Discussion
11β-Hydroxylase deficiency represents the second most common cause of CAH with a frequency of 5-8 % after the much more frequent 21-hydroxylase deficiency. These patients often do not come to a molecular diagnosis nor to an appropriate hormonal evaluation and their condition remains misunderstood as 21 hydroxylase deficiency, at least in our experience in Italy.
Therefore, after having improved the hormonal evaluation, developed a standard molecular analysis method and studied the new mutations identified as described in a previous paper [16] , we focused on how to identify also the possible rearrangements or deletions of the CYP11B1 gene.
To date a total of five gross rearrangements/deletions were reported: four chimeric genes with different break points [12] [13] [14] [15] and a deletion of 449 bp encompassing part of exon 3 and all the exon 4 of the CYP11B1 gene [19] . These previous hybrid genes were identified by time-consuming methods and not within the reach of all laboratories such as Southern blot and cell expression studies.
As we needed to know the CYP11B1 gene rearrangement with a rapid and repeatable technique, we decided on a home-made MLPA semiquantitative method to be able to detect in a single step the presence of a chimeric gene (that includes the analysis of the homologous CYP11B2 gene) as well as other types of deletions.
The use of the MLPA technique with specific probes for both CYP11B1 and CYP11B2 has obtained this result, and in particular, identified a novel CYP11B2/CYP11B1 chimeric gene, with the breakpoint region localized in the second intron.
The other hybrid genes reported [12] [13] [14] [15] had different break point sites ranging from exon 3 to exon 6 of the CYP11B2 gene; all of them were associated with a complete loss of the 11β-hydroxylase activity.
This deficiency is due to the failure of expression of the chimeric gene in the fasciculata/reticularis zona through the CYP11B2 promoter regulation [20] ; therefore, the effect of the hybrid gene is identical to that of an inactivating mutation of the CYP11B1 gene.
With this method we were able to demonstrate that our patient is a compound heterozygote for the severe mutation p.A306V [16] and the chimeric gene, thus correctly defining his genotype. The clinical and phenotypic data of our patient confirmed that the hybrid gene and the p.A306V mutation behaved as null alleles.
This new method used to investigate the copy number variations in the CYP11B1 gene proved to be very reliable, easy and rapid. The power of this technique is not only to detect the chimeric gene in both the homozygous and heterozygous state but also to evaluate the entire gene or single exon deletions.
In addition it can be used also to point out the presence of the opposite CYP11B1/CYP11B2 chimaera associated with GRA.
In conclusion, we believe that the MLPA method with the set of probes here proposed represents an easy, quick and economical method for CYP11B1 gene deletion research and that it can be commonly used, in addition to complete gene sequencing, for the molecular diagnosis of 11OHD. Furthermore, we believe that it can contribute to the re-evaluation of the frequency of this kind of deleterious allele among the mutations causing 11OHD, although they are presumably rare.
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